These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 3260132)

  • 1. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
    Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
    Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a combination of cyclophosphamide and human recombinant interleukin 2 on pulmonary metastasis after the surgical removal of a 3-methylcholanthrene-induced primary tumor in autochthonous mice.
    Hosokawa M; Yabiku T; Ikeda J; Sawamura Y; Okada F; Komatsumoto M; Tanabe T; Kobayashi H
    Jpn J Cancer Res; 1988 Oct; 79(10):1147-54. PubMed ID: 3143703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
    Fukuta K; Sone S; Kitahara M; Okada M; Ogura T
    Jpn J Cancer Res; 1989 Jun; 80(6):562-7. PubMed ID: 2503476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.
    Gazit Z; Kedar E
    Cancer Immunol Immunother; 1994 Apr; 38(4):243-52. PubMed ID: 8168119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A study to increase the therapeutic effects of adoptive immunotherapy in vivo. Influence on the generation of lymphokine activated killer (LAK) cells and therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide)].
    Yoshimori K
    Nihon Ika Daigaku Zasshi; 1992 Oct; 59(5):418-27. PubMed ID: 1430114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
    Eggermont AM; Sugarbaker PH
    Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
    Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
    Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E; Ben-Aziz R; Shiloni E
    Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
    Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
    Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.
    Eggermont AM; Sugarbaker PH
    Br J Cancer; 1988 Oct; 58(4):410-4. PubMed ID: 3264714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
    Yang ZB
    Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.
    Stewart LS; Sewell HF; Thomson AW
    Clin Exp Immunol; 1990 Mar; 79(3):416-23. PubMed ID: 2317946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models.
    Eggermont AM; Sugarbaker PH; Marquet RL; Jeekel J
    Cancer Immunol Immunother; 1988; 26(1):23-30. PubMed ID: 3257900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.